CSI Market
Sign In | Register

Nuo Therapeutics Inc (NUOT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NUOT Annual Cash Flow →
From Nuo Therapeutics Inc through Mar 31 2025, changes in Mar 31 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-0.62
Depreciation & amortization0.02
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.03
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.04
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.17
Gain Loss On Derivative Instruments Net Pretax-
Amortization Of Deferred Charges-
Gains Losses On Restructuring Of Debt-
Provision For Reduction Of Doubtful Accounts-
Allowance For Doubtful Accounts Receivable Period Increase Decrease-
Amendment To Contingent Consideration Effect On Income-
Extinguishment Of Debt Gain Loss Net Of Tax-
Issuance Of Warrants Effect On Income-
Loss On Abandonment-
Reorganization Value Present Value Of Discounted Cash Flows Of Emerging Entity-
Stock Issued0.00
Gain On Settlement Of Accounts Payable-
Operating Lease Right Of Use Asset Amortization Expense0.02
Increase Decrease In Prepaid Expense And Other Current Assets-0.08
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.31
Increase (Decrease) in Accounts Payable-0.05
Increase (Decrease) in Accrued Liabilities0.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.02
Discontinued operations0.00
Net Cash flow from Operating Activities-0.78
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Property Plant And Equipments-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.50
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.55
Proceeds From Issuance Of Preferred Stock And Warrants Net-
Proceeds From Stock Option And Warrant Excercises-
Proceeds From Short Term And Long Term Convertible Debt-
Proceeds From Issuance Of Convertable Debt-
Repayment Of Note Payable-
Proceeds From Stock Option And Warrant Exercises-
Proceeds From Issuance Of Convertible Debt-
Proceeds From Sale Of Preferred Stock And Warrants Net-
Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Issuance Costs-
Proceeds From Issuance Of Commonstock And Preferred Stock Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.55
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.50
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.79
Total Cash Flow-0.29
4 historic quarters locked

Sign in to unlock the full Nuo Therapeutics Inc cash flow history.

Sign In Create Free Account

About Nuo Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-028053

Figures are derived from filed reports and may be restated. Historical data is subject to revision.